Mitoxantrone Recruiting Phase 1 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Childhood Acute Monoblastic Leukemia (M5a) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Childhood Acute Monocytic Leukemia (M5b) / Adult Acute Monoblastic Leukemia (M5a) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloid Leukemia in Remission / Adult Erythroleukemia (M6a) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Erythroleukemia (M6) / Untreated Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Adult Pure Erythroid Leukemia (M6b) / Adult Acute Myeloid Leukemia With Del(5q) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloblastic Leukemia With Maturation (M2) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01801046Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia